Singapore-based biopharmaceutical firm Prestige BioPharma (PBP) has commenced construction of Innovative Discovery Center (IDC) in Busan, South Korea.
The firm plans to complete construction of IDC by February 2023.
With a total area of approximately 34,000m2, the global-scale R&D centre will have facilities that can accommodate 800 researchers.
PBP and Busan City Government signed a memorandum of understanding (MOU) earlier in May 2021 for the establishment of IDC with an investment of more than $200m by 2030.
PBP CEO Dr Lisa S Park said: “IDC will be leading PBP Group’s innovative drug discovery R&D in connection with our research centers in Singapore and US and creating a global open innovation hub for industry-academic collaboration and we envision IDC where Prestige Biopharma’s innovation realizes and the start of a new world-class bio-cluster here in Busan.”
PBP said that the IDC will focus on discovery of first-in-class antibody biologics, beginning from eight bispecific antibody projects.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe IDC will focus on the development of next generation vaccines using mRNA technologies and bioinformatics.
Busan City Mayor Hyeong-joon Park said: “Busan City will fully support PBP’s IDC so this novel partnership can lead a local bio-industry’s growth and contribute to local economic development and high-quality job creation.”
Furthermore, IDC is expected to lead the bioindustry growth in Busan, while laying a foundation to make the region a viable bio-cluster.
By implementing an open innovation platform, IDC plans to provide local biomedical society with a ‘one stop’ R&D solution for full development cycle of new drugs targeting global markets.
Over the next five years, IDC is expected to employ more than 250 PhD and R&D personnel.
—————————————————————————————————————–
Prestige BioPharma’s Innovative Discovery Center in Busan, Korea. Credit: Business Wire.